Cargando…

Cardiovascular benefits from SGLT2 inhibition in type 2 diabetes mellitus patients is not impaired with phosphate flux related to pharmacotherapy

The beneficial cardiorenal outcomes of sodium-glucose cotransporter 2 inhibitors (SGLT2i) in patients with type 2 diabetes mellitus (T2DM) have been substantiated by multiple clinical trials, resulting in increased interest in the multifarious pathways by which their mechanisms act. The principal ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nashawi, Mouhamed, Ahmed, Mahmoud S, Amin, Toka, Abualfoul, Mujahed, Chilton, Robert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8716977/ https://www.ncbi.nlm.nih.gov/pubmed/35070111 http://dx.doi.org/10.4330/wjc.v13.i12.676

Ejemplares similares

Benefits of SGLT2 inhibitors in arrhythmias
por: Gao, Jinghan, et al.
Publicado: (2022)

DELIVER: Extending the benefits of SGLT-2 inhibitors
por: Samaan, Kerollos, et al.
Publicado: (2023)

Cardiovascular and Renal Benefits of SGLT2 Inhibitors: A Narrative Review
por: Rabizadeh, Soghra, et al.
Publicado: (2019)

Preventive pharmacotherapy in type 2 diabetes mellitus
por: Choudhary, Neeraj, et al.
Publicado: (2012)

Comparison of cardiovascular outcomes between SGLT2 inhibitors in diabetes mellitus
por: Suzuki, Yuta, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
por: Aftab, Saba, et al.
Publicado: (2020)

Acute Retinal Necrosis in an Immunocompetent Patient Treated With Intravitreal Ganciclovir
por: Nashawi, Mouhamed, et al.
Publicado: (2021)

Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus
por: Rehman, Saad U, et al.
Publicado: (2020)

A CASE OF FATAL COVID-19 FULMINANT MYOCARDITIS IN A YOUNG WOMAN WITH NO CARDIOVASCULAR MEDICAL HISTORY: GETTING TO THE HEART OF CORONAVIRUS COMPLICATIONS
por: Ahmed, Mahmoud Samy, et al.
Publicado: (2021)

Does SGLT1 inhibition add to the benefits of SGLT2 inhibition in the prevention and treatment of heart failure?
por: Pitt, Bertram, et al.
Publicado: (2022)

Benefits of SGLT2 Inhibitor: Preventing Heart Failure and Beyond
por: Kim, Yong Sook, et al.
Publicado: (2019)

Optimising the Benefits of SGLT2 Inhibitors for Type 1 Diabetes
por: Evans, Marc, et al.
Publicado: (2019)

Cases and etiologies of suspected COVID-19 reactivation
por: Ghali, Abdullah, et al.
Publicado: (2020)

SGLT-2 Inhibitors and Cardiovascular Protection: Lessons and Gaps in Understanding the Current Outcome Trials and Possible Benefits of Combining SGLT-2 Inhibitors With GLP-1 Agonists
por: Abdelgadir, Elamin, et al.
Publicado: (2018)

Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors: Delving Into the Potential Benefits of Cardiorenal Protection Beyond the Treatment of Type-2 Diabetes Mellitus
por: Srinivas, Natasha, et al.
Publicado: (2021)

The SGLT-2 Inhibitors in Personalized Therapy of Diabetes Mellitus Patients
por: Tilinca, Mariana Cornelia, et al.
Publicado: (2021)

The Intersection of SGLT2 Inhibitors, Cognitive Impairment, and CKD
por: Noel, J. Ariana, et al.
Publicado: (2022)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Benefits Versus Risk
por: Jasleen, Bains, et al.
Publicado: (2023)

Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: Harms or Unexpected Benefits?
por: Andreea, Munteanu Madalina, et al.
Publicado: (2023)

Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors
por: Margonato, Davide, et al.
Publicado: (2020)

Multi-omics insights into potential mechanism of SGLT2 inhibitors cardiovascular benefit in diabetic cardiomyopathy
por: Xi, Yangbo, et al.
Publicado: (2022)

Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review
por: Georgiou, Petros, et al.
Publicado: (2021)

Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus
por: Kaushal, Shaveta, et al.
Publicado: (2014)

Are SGLT2 polymorphisms linked to diabetes mellitus and cardiovascular disease? Prospective study and meta-analysis
por: Drexel, Heinz, et al.
Publicado: (2019)

Does Gender Influence the Cardiovascular Benefits Observed with Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors? A Meta-Regression Analysis
por: Mahmoud, Ahmed N., et al.
Publicado: (2016)

The Role of Combined SGLT1/SGLT2 Inhibition in Reducing the Incidence of Stroke and Myocardial Infarction in Patients with Type 2 Diabetes Mellitus
por: Pitt, Bertram, et al.
Publicado: (2021)

Pharmacotherapy of mild cognitive impairment
por: Gauthier, Serge
Publicado: (2004)

Pharmacotherapy of Posttraumatic Cognitive Impairments
por: Arciniegas, David B., et al.
Publicado: (2006)

An Update on the Molecular and Cellular Basis of Pharmacotherapy in Type 2 Diabetes Mellitus
por: Mahgoub, Mohamed Omer, et al.
Publicado: (2023)

Use of SGLT-2 Inhibitors in Patients With Type 1 Diabetes Mellitus
por: El Hage, Lea, et al.
Publicado: (2020)

Can SGLT2 Inhibitor be Used for Diabetes Mellitus or Vascular Diseases?
por: Nomiyama, Takashi
Publicado: (2020)

SGLT2 Inhibitors: Cardiovascular Benefits Beyond HbA1c—Translating Evidence into Practice
por: Ali, Amar, et al.
Publicado: (2019)

Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus
por: Peppa, Melpomeni, et al.
Publicado: (2023)

Prosthetic mitral valve Aspergillus fumigatus endocarditis
por: Museedi, Abdulrahman S., et al.
Publicado: (2020)

A Rare Presentation of Omental Lymphangioma Masquerading as Malignancy in an Adult Patient
por: Alameri, Aws, et al.
Publicado: (2020)

Correction to: A Rare Presentation of Omental Lymphangioma Masquerading as Malignancy in an Adult Patient
por: Alameri, Aws, et al.
Publicado: (2021)

Impact of demographic characteristics and antihyperglycemic and cardiovascular drugs on the cardiorenal benefits of SGLT2 inhibitors in patients with type 2 diabetes mellitus: A protocol for systematic review and meta-analysis
por: Chang, Rong, et al.
Publicado: (2021)

Basic mechanisms of urgency: roles and benefits of pharmacotherapy
por: Michel, Martin Christian, et al.
Publicado: (2009)

Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review
por: Lopaschuk, Gary D., et al.
Publicado: (2020)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_sq6o951064ad60qr7ttvr7acjg